Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Guisado-Vasco
Guisado-Vasco, Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary..,
Retrospective 607 patients reporting results for early outpatient HCQ use with mortality odds ratio OR 0.092 [0.022-0.381], p = 0.001 (65 patients), and for hospital use, mortality odds ratio OR 0.737 [0.38-1.41], p = 0.36 (558 patients). Median age 69.
risk of death, 20.3% lower, RR 0.80, p = 0.36, treatment 127 of 558 (22.8%), control 14 of 49 (28.6%), NNT 17, adjusted per study, odds ratio converted to relative risk.
outpatient use, 88.0% lower, RR 0.12, p = 0.001, treatment 2 of 65 (3.1%), control 139 of 542 (25.6%), NNT 4.4, adjusted per study, odds ratio converted to relative risk.
Abstract: EClinicalMedicine 28 (2020) 100591
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicine
Research Paper
Clinical characteristics and outcomes among hospitalized adults with
severe COVID-19 admitted to a tertiary medical center and receiving
antiviral, antimalarials, glucocorticoids, or immunomodulation with
tocilizumab or cyclosporine: A retrospective observational study
(COQUIMA cohort)
n-Gonza
leza,
Pablo Guisado-Vascoa,*, Sofia Valderas-Ortegab, Maria Maravillas Carralo
c
d
a
lez-Cortijo , Gabriel Sotres-Ferna
ndez ,
Ana Roda-Santacruz , Lucia Gonza
e
a
Eva María Martí-Ballesteros , Jose Manuel Luque-Pinilla , Elena Almagro-Casadod,
lix J. La Coma-Lanuzaf, Ruth Barrena-Puertasa, Esteban Javier Malo-Benagesg,
Fe
Monforte-Go
mezh, Rocío Diez-Munari, Esther Merino-Lanzaj,
María Jose
Lorena Comeche-Casanovak, Margarita Remirez-de-Esparza-Oterol, María Correyero-Plazam,
pezo, María Dolores Sa
nchez-Manzanoa,
Manuel Recio-Rodríguezn, Margarita Rodríguez-Lo
zquezp, Israel John Thuissard-Vasallop,
Cristina Andreu-Va
María Echave-Sustaeta María-Tome
k, Daniel Carnevali-Ruiza
Jose
a
Department of Internal Medicine. Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain
Nurse. Hospital Infectious Diseases Control Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
Research coordinator. Research and clinical trials unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
d
Department of Oncology. Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain
e
Department of Hematology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
f
Intensive Care Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
g
Department of Angiology and Vascular Surgery, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
h
Department of Internal Medicine, Hospital quironsalud San Jose, Madrid, Spain
i
Department of Anesthesiology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
j
Department of Cardiology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
k
Department of Pneumology, Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain
l
Pharmacy Unit, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
m
Department of Rheumatology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
n
Department of Radiology department, Hospital universitario quironsalud Madrid, Universidad Europea (Madrid), Pozuelo de Alarcon, Madrid, Spain
o
Department of Endocrinology, Hospital universitario quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
p
n, Madrid, Spain
Statistical section, Faculty of Biomedical Science and Health, Universidad Europea (Madrid), Villaciosa de Odo
b
c
A R T I C L E
I N F O
Article History:
Received 8 July 2020
Revised 22 September 2020
Accepted 25 September 2020
Available online 15 October 2020
Keywords:
Severe COVID-19
SARS-CoV-2 infection
Cyclosporine a
Acute respiratory insufficiency
Immunosuppressants
Hyperinflammation state
A B S T R A C T
Background: The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available
therapies..
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.